Vaxart Balance Sheet Health
Financial Health criteria checks 5/6
Vaxart has a total shareholder equity of $68.4M and total debt of $4.9M, which brings its debt-to-equity ratio to 7.1%. Its total assets and total liabilities are $166.7M and $98.2M respectively.
Key information
7.1%
Debt to equity ratio
US$4.88m
Debt
| Interest coverage ratio | n/a |
| Cash | US$58.71m |
| Equity | US$68.44m |
| Total liabilities | US$98.23m |
| Total assets | US$166.67m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NB11's short term assets ($66.5M) do not cover its short term liabilities ($80.4M).
Long Term Liabilities: NB11's short term assets ($66.5M) exceed its long term liabilities ($17.9M).
Debt to Equity History and Analysis
Debt Level: NB11 has more cash than its total debt.
Reducing Debt: NB11's debt to equity ratio has reduced from 98.4% to 7.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NB11 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NB11 has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 29.2% each year.